The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients

Akyol, Ömer; Herken, Hasan; Uz, Efkan; Fadıllıoğlu, Ersin; Ünal, Süheyla; Söğüt, Sadık; Özyurt, Hüseyın; Savaş, Haluk A.

doi:10.1016/s0278-5846(02)00220-8

Cited by 255 publications

(150 citation statements)

References 73 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Reduced levels of the major antioxidant enzymes, superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px), have also been found in patients with schizophrenia compared with controls (Ben Othmen et al, 2007;Li et al, 2006;Ranjekar et al, 2003). Others have reported unchanged levels for these three enzymes (Srivastava et al, 2001), or altered concentrations of individual enzymes (Abdalla et al, 1986;Akyol et al, 2002;Altuntas et al, 2000;DietrichMuszalska et al, 2005;Herken et al, 2001;Kuloglu et al, 2002c ;Zhang et al, 2006a). A strong negative correlation between blood GSH-Px and structural measures of brain atrophy was also reported by an early study (Buckman et al, 1987).…”

Section: Assays Of Oxidants and Antioxidantsmentioning

confidence: 99%

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Berk

Dean

et al. 2008

Int. J. Neuropsychopharm.

878

569

View full text Add to dashboard Cite

Oxidative stress has been implicated in the pathogenesis of diverse disease states, and may be a common pathogenic mechanism underlying many major psychiatric disorders, as the brain has comparatively greater vulnerability to oxidative damage. This review aims to examine the current evidence for the role of oxidative stress in psychiatric disorders, and its academic and clinical implications. A literature search was conducted using the Medline, Pubmed, PsycINFO, CINAHL PLUS, BIOSIS Previews, and Cochrane databases, with a time-frame extending to September 2007. The broadest data for oxidative stress mechanisms have been derived from studies conducted in schizophrenia, where evidence is available from different areas of oxidative research, including oxidative marker assays, psychopharmacology studies, and clinical trials of antioxidants. For bipolar disorder and depression, a solid foundation for oxidative stress hypotheses has been provided by biochemical, genetic, pharmacological, preclinical therapeutic studies and one clinical trial. Oxidative pathophysiology in anxiety disorders is strongly supported by animal models, and also by human biochemical data. Pilot studies have suggested efficacy of N-acetylcysteine in cocaine dependence, while early evidence is accumulating for oxidative mechanisms in autism and attention deficit hyperactivity disorder. In conclusion, multi-dimensional data support the role of oxidative stress in diverse psychiatric disorders. These data not only suggest that oxidative mechanisms may form unifying common pathogenic pathways in psychiatric disorders, but also introduce new targets for the development of therapeutic interventions.

show abstract

Section: Assays Of Oxidants and Antioxidantsmentioning

confidence: 99%

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Berk

Dean

et al. 2008

Int. J. Neuropsychopharm.

878

569

View full text Add to dashboard Cite

show abstract

“…Although NO is described as an atypical neurotransmitter in the nervous system, it seems more appropriate to place it in the second messenger. 17 NO is produced by the family of nitric oxide synthase (NOS) and is known to affect the neurodevelopmental process in the CNS. 18 Therefore, it should be very valuable to determine the interference of NO generation in schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Total antioxidant response in patients with schizophrenia

Üstündağ¹,

Atmaca

Kirtaş

et al. 2006

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

There is a large amount of convincing data demonstrating that reactive oxygen species (ROS) are involved in initiation and development of many different forms of neuropsychiatric disorders. The levels of oxidants and antioxidants in schizophrenia have been evaluated. However, measurements of total antioxidant response (TAR) were not evaluated up to now. Therefore, the objectives of this study are to investigate plasma TAR levels in schizophrenia subtypes. A total of 76 patients with schizophrenia and 25 healthy volunteers were included in the study. Positive and Negative Syndrome Scale (SANS and SAPS, respectively) were applied to patients. TAR values were determined in the plasma of normal healthy controls and patients with schizophrenia. Plasma TAR levels of each schizophrenia subtype were significantly lower than healthy controls (P < 0.01 for disorganized, residual and undifferentiated subtypes and P < 0.01 for paranoid subtype). When intragroup comparisons were performed, paranoid subtype had higher plasma TAR levels compared to other subtypes (P < 0.01). Accordingly, as a whole group, patients with schizophrenia had lower plasma TAR levels compared to controls. Plasma TAR levels were significantly and negatively correlated with SANS scores, and duration of illness was evaluated but not related to other parameters. Consequently, the present study further emphasizes the growing consideration that free radical damage may have an important etiopathogenetic role on the development of schizophrenia and suggests that decreased plasma total antioxidant levels may be related to the progression of illness.

show abstract

“…Studies examining the oxidative metabolism in patients with schizophrenia established that TOS level and OSI values and other oxidant parameters were signifi cantly higher in patients with schizophrenia than those in controls (17)(18)(19)(20). Although there are studies generally demonstrating increase of oxidants in patients with schizophrenia, a few have shown that there was no change (21,22).…”

Section: Discussionmentioning

confidence: 99%

Elevated nucleosome level and oxidative stress in schizophrenia patients

Bahçeci¹,

Mh²,

Us³

et al. 2015

BLL

View full text Add to dashboard Cite

AIM: The aim of this study was to investigate the effect of oxidative stress on nucleosome levels and its relation with the clinical features in schizophrenia patients. MATERIAL AND METHOD: Thirty schizophrenia patients and 30 healthy controls were enrolled in this study. Patients were diagnosed with schizophrenia according to the 4th edition of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV). The control group consisted of 30 healthy subjects matched to the patients with regard to age and gender and who had no history of any psychiatric disorder. The severity of schizophrenia symptoms in the patients was evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Severity Scale (CGI-S). Physical and neurological examinations were performed in each of the patients and controls. RESULTS: Nucleosome, total oxidant levels and OSI values were higher in schizophrenia patients than in controls (p < 0.05). There was no signifi cant difference in the total antioxidant levels. There was a positive correlation between the nucleosome level and PANSS positive subscale (p = 0.028, r = 0.402). There was a positive correlation between TAS and age (p = 0.025, r = 0.289), PANSS total (p < 0.001, r = 0.604). There was a negative correlation between OSI and PANSS total (p = 0.019, r = -0.427), PANSS positive subscale (p = 0.043, r = -0.372). There was a negative correlation between TOS and PANS total (p = 0.028, r = -0.402). CONCLUSION: In this study we found a correlation between nucleosome level and PANSS positive subscale. To our knowledge, this is the fi rst study that evaluates oxidative stress and nucleosomes released from apoptotic cells together (Tab. 2, Ref. 50). Text in PDF www.elis.sk.

show abstract

The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients

Cited by 255 publications

References 73 publications

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Total antioxidant response in patients with schizophrenia

Elevated nucleosome level and oxidative stress in schizophrenia patients

Contact Info

Product

Resources

About